Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial

Pharmacogenomics Journal

Volumn 11, Issue 2, 2011, Pages 100-107

  Serrano, D ^a   Lazzeroni, M ^a,b   Zambon, C F ^c   MacIs, D ^a   Maisonneuve, P ^a   Johansson, H ^a   Guerrieri Gonzaga, A ^a   Plebani, M ^c   Basso, D ^c   Gjerde, J ^d   Mellgren, G ^d,e   Rotmensz, N ^a   Decensi, A ^a,f   Bonanni, B ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF BERGEN   (Norway)

^f GALLIERA HOSPITAL   (Italy)

Author keywords

breast cancer; chemoprevention; CYP2D6; genotype; tamoxifen

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; PLACEBO; SULFOTRANSFERASE 1A1; TAMOXIFEN;

ADULT; AGED; ALLELE; ARTICLE; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; CAUCASIAN; CONTROLLED STUDY; DRUG EFFICACY; DRUG METABOLISM; FEMALE; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYSTERECTOMY; ITALY; MAJOR CLINICAL STUDY; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTINEOPLASTIC AGENTS, HORMONAL; ARYL HYDROCARBON HYDROXYLASES; ARYLSULFOTRANSFERASE; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CLINICAL TRIALS AS TOPIC; CYTOCHROME P-450 CYP2D6; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; ITALY; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; TAMOXIFEN; TREATMENT OUTCOME;

EID: 77957559661     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2010.17     Document Type: Article

References (44)

1. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005; 97: 1652-1662. (Pubitemid 41672231)
2. Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the national surgical adjuvant breast and bowel project experience. Semin Oncol 2001; 28: 400-418. (Pubitemid 32762083)
3. Colleoni M, Gelber S, Goldhirsch A, Aebi S, Castiglione-Gertsch M, Price KN et al. Tamoxifen after adjuvant chemotherapy for premeno-pausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol 2006; 24: 1332-1341. (Pubitemid 46621995)
4. Fentiman IS, Fourquet A, Hortobagyi GN. Male breast cancer. Lancet 2006; 367: 595-604. (Pubitemid 43247575)
5. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet 1989; 45: 889-904. (Pubitemid 20045231)
6. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005; 352: 2211-2221.
7. Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics 2007; 17: 93-101.
8. Wedlund PJ. The CYP2C19 enzyme polymorphism. Pharmacology 2000; 61: 174-183.
9. Ellis KJ, Stouffer GA, McLeod HL, Lee CR. Clopidogrel pharmacoge-nomics and risk of inadequate platelet inhibition: US FDA recommendations. Pharmacogenomics 2009; 10: 1799-1817.
10. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjoqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993; 90: 11825-11829. (Pubitemid 24008732)
11. Rodriguez-Antona C, Ingelman-Sundberg M. Cytochrome P450 phar-macogenetics and cancer. Oncogene 2006; 25: 1679-1691.
12. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006; 79: 103-113. (Pubitemid 43069582)
13. Jordan VC. Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance. Breast Cancer Res Treat 1982; 2: 123-138. (Pubitemid 13233530)
14. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P et al. Active tamoxifen metabolite plasma concentrations after coadministra-tion of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003; 95: 1758-1764. (Pubitemid 38008898)
15. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005; 97: 30-39.
16. Wu X, Hawse JR, Subramaniam M, Goetz MP, Ingle JN, Spelsberg TC. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. Cancer Res 2009; 69: 1722-1727.
17. Boocock DJ, Brown K, Gibbs AH, Sanchez E, Turteltaub KW, White IN. Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. Carcinogenesis 2002; 23: 1897-1901. (Pubitemid 35355938)
18. Justenhoven C, Hamann U, Pierl CB, Baisch C, Harth V, Rabstein S et al. CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat 2009; 115: 391-396.
19. Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, Zanger UM et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 2007; 25: 5187-5193. (Pubitemid 350232249)
20. Nowell S, Sweeney C, Winters M, Stone A, Lang NP, Hutchins LF et al. Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy. J Natl Cancer Inst 2002; 94: 1635-1640. (Pubitemid 35378729)
21. Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 2006; 80: 61-74. (Pubitemid 43946844)
22. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005; 23: 9312-9318.
23. Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2007; 101: 113-121. (Pubitemid 47555336)
24. Veronesi U, Maisonneuve P, Rotmensz N, Costa A, Sacchini V, Travaglini R et al. Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst 2003; 95: 160-165. (Pubitemid 36193265)
25. Bonanni B, Macis D, Maisonneuve P, Johansson H, Gucciardo G, Oliviero P et al. Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial. J Clin Oncol 2006; 24: 3708-3709. (Pubitemid 46630548)
26. Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 1998; 352: 93-97. (Pubitemid 28321320)
27. Veronesi U, Maisonneuve P, Rotmensz N, Bonanni B, Boyle P, Viale G et al. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst 2007; 99: 727-737. (Pubitemid 47073533)
28. Zambon CF, Fasolo M, Basso D, D'Odorico A, Stranges A, Navaglia F et al. Clarithromycin resistance, tumor necrosis factor alpha gene polymorphism and mucosal inflammation affect H. pylori eradication success. J Gastrointest Surg 2007; 11: 1506-1514.
29. Gjerde J, Hauglid M, Breilid H, Lundgren S, Varhaug JE, Kisanga ER et al. Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann Oncol 2008; 19: 56-61.
30. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998; 339: 1609-1618. (Pubitemid 28536137)
31. Goetz M, Ames M, Gnant M, Filpits M, Jakesz R, Greil R et al. Pharmacogenetic (CYP2D6) and gene expression profiles (HOXB13/ IL17BR and molecular grade index) for prediction of adjuvant endocrine therapy benefit in the ABCSG 8 trial. Paper presented at 30th Annual SABCS 10-14 December 2008; San Antonio, TX2008. (Abstract 57).
32. Gaedigk A, Ryder DL, Bradford LD, Leeder JS. CYP2D6 poor metabolizer status can be ruled out by a single genotyping assay for the -1584G promoter polymorphism. Clin Chem 2003; 49: 1008-1011. (Pubitemid 36623498)
33. Zanger UM, Fischer J, Raimundo S, Stuven T, Evert BO, Schwab M et al. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 2001; 11: 573-585. (Pubitemid 32953583)
34. Winer EP. Optimizing endocrine therapy for breast cancer. J Clin Oncol 2005; 23: 1609-1610. (Pubitemid 46211411)
35. Punglia RS, Burstein HJ, Winer EP, Weeks JC. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst 2008; 100: 642-648.
36. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 106: 2329-2333. (Pubitemid 41510803)
37. Irvin WJ, Carey LA, Dees EC, Lange L, Chiu WK, Evans JP et al. Validating CYP2D6 genotype-guided tamoxifen therapy for a multiracial US population. San Antonio Breast Cancer Symposium 2009. (Abstract 410).
38. Decensi A, Robertson C, Viale G, Pigatto F, Johansson H, Kisanga ER et al. A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst 2003; 95: 779-790. (Pubitemid 36798424)
39. Guerrieri-Gonzaga A, Robertson C, Bonanni B, Serrano D, Cazzaniga M, Mora S et al. Preliminary results on safety and activity of a randomized, double-blind, 2x2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in premenopausal women. J Clin Oncol 2006; 24: 129-135. (Pubitemid 46630503)
40. Decensi A, Robertson C, Guerrieri-Gonzaga A, Serrano D, Cazzaniga M, Mora S et al. Randomized double-blind 2x2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women. J Clin Oncol 2009; 27: 3749-3756.
41. Bonanni B, Serrano D, Gandini S, Guerrieri-Gonzaga A, Johansson H, Macis D et al. Randomized biomarker trial of anastrozole or low-dose tamoxifen or their combination in subjects with breast intraepithelial neoplasia. Clin Cancer Res 2009; 15: 7053-7060.
42. Wegman P, Elingarami S, Carstensen J, Stal O, Nordenskjold B, Wingren S. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 2007; 9: R7.
43. Nowell SA, Ahn J, Rae JM, Scheys JO, Trovato A, Sweeney C et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 2005; 91: 249-258. (Pubitemid 40903087)
44. Goetz MP, Berry DA, Klein TE. Adjuvant tamoxifen treatment outcome according to cytochrome P450 2D6 (CYP2D6) phenotype in early stage breast cancer: findings from the International Tamoxifen Pharmacoge-nomics Consortium. San Antonio Breast Cancer Symposium 2009. (Abstract 33).